Nykode Therapeutics Stock
Stocks
VACC
NO0010714785
Biotechnology & Medical Research
OTC Markets Traded|
Real-time
Oslo Bors
12:44:22 23/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 3.170 NOK | -1.40% |
|
+1.44% | +31.43% |
| 09-28 | Nykode Therapeutics Gets Unfavorable Tax Appeal Board Ruling, Plans to Seek Review | MT |
| 08-28 | Nykode Therapeutics Raises NOK286 Million via Share Placement | MT |
| Market Cap | 1.05B 112M 100M 92.41M 83.96M 158M 10.63B 160M 1.11B 439M 5.57B 421M 412M 17.64B | P/E 2026 * |
-4.89x | P/E 2027 * | 61.2x |
|---|---|---|---|---|---|
| Enterprise Value | 561M 59.99M 53.55M 49.4M 44.88M 84.2M 5.68B 85.5M 595M 234M 2.98B 225M 220M 9.43B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 1.95x |
| Free-Float |
76.21% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Oslo Bors
| VACC | Real-time | |
CBOE
| Real-time | ||
|
Nasdaq Stockholm
| NYKD O | Delayed | |
|
OTC Markets
| VACBF | Delayed | |
|
Börse Stuttgart
| 5VB | Delayed | |
|
Boerse Muenchen
| 5VB | Real-time | |
|
Deutsche Boerse AG
| 5VB | Delayed | |
|
CBOE
| Real-time |
Last Transcript: Nykode Therapeutics
| 1 day | -1.24% | ||
| 1 week | +1.60% | ||
| Current month | -11.06% | ||
| 1 month | -19.31% | ||
| 3 months | +3.25% | ||
| 6 months | -0.31% | ||
| Current year | +31.63% |
| 1 week | 3.1 |  | 3.35 |
| 1 month | 3.02 | | 3.96 |
| Current year | 2.21 | | 5.2 |
| 1 year | 2.06 | | 5.2 |
| 3 years | 1.44 | | 21.62 |
| 5 years | 1.44 | | 85.3 |
| 10 years | 1.44 | | 93 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 49 | 01/01/2017 | |
Michael Engsig
CEO | Chief Executive Officer | 54 | 01/01/2019 |
Harald Gurvin
DFI | Director of Finance/CFO | 51 | 03/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | - | |
Trygve Lauvdal
BRD | Director/Board Member | 57 | - |
Susanne Stuffers
CHM | Chairman | 45 | 23/04/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/27/25 A | Buy | Company | 3,000,000 | 0.9187% | ||
| 12/20/24 A | Buy | Director | 100,000 | 0.0306% | ||
| 12/20/24 A | Sell | Director | 100,000 | 0.0306% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.24% | +1.60% | +32.85% | -83.80% | 112M | |
| -4.10% | -8.54% | +40.05% | +66.99% | 63.29B | |
| -0.74% | +6.82% | +10.30% | +72.37% | 54.89B | |
| -0.16% | +3.94% | +9.37% | +91.64% | 53.28B | |
| +0.61% | +2.69% | +27.75% | +50.97% | 45.81B | |
| -1.08% | +2.19% | +21.92% | +131.38% | 43.46B | |
| -3.39% | -0.83% | +254.27% | +571.04% | 40.23B | |
| -1.67% | +6.70% | +14.42% | +56.67% | 33.45B | |
| +1.19% | -4.98% | +29.01% | -0.76% | 23.7B | |
| -0.85% | +5.04% | +35.60% | +26.77% | 23.76B | |
| Average | -1.14% | +0.70% | +47.55% | +98.33% | 38.2B | |
| Weighted average by Cap. | -1.33% | +0.60% | +47.31% | +122.04% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 214M 22.84M 20.39M 18.81M 17.09M 32.06M 2.16B 32.55M 227M 89.26M 1.13B 85.74M 83.9M 3.59B |
| Net income | -211M -22.59M -20.17M -18.61M -16.9M -31.71M -2.14B -32.2M -224M -88.29M -1.12B -84.81M -82.99M -3.55B | 11.3M 1.21M 1.08M 995K 904K 1.7M 114M 1.72M 11.98M 4.72M 59.94M 4.53M 4.44M 190M |
| Net Debt | -489M -52.23M -46.62M -43.01M -39.07M -73.3M -4.95B -74.43M -518M -204M -2.59B -196M -192M -8.21B | -634M -67.78M -60.5M -55.82M -50.71M -95.13M -6.42B -96.6M -672M -265M -3.36B -254M -249M -10.66B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/10/26 | NOK 3.170 | -1.40% | 501,823 |
| 22/10/26 | NOK 3.215 | -3.16% | 769,630 |
| 21/10/26 | NOK 3.320 | +4.40% | 1,089,822 |
| 20/10/26 | NOK 3.180 | -0.31% | 361,457 |
| 19/10/26 | NOK 3.190 | +2.08% | 1,277,181 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VACC Stock
Select your edition
All financial news and data tailored to specific country editions
